Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The balance of intake of n-6 and n-3 PUFA, and consequently their relative incorporation into immune cells, is important in determining the development and severity of immune and inflammatory responses. Some disorders characterised by exaggerated inflammation and excessive formation of inflammatory markers have become among the most important causes of death and disability in man in modern societies. The recognition that long-chain n-3 PUFA have the potential to inhibit (excessive) inflammatory responses has led to a large number of clinical investigations with these fatty acids in inflammatory conditions as well as in healthy subjects. The present review explores the presence of dose-related effects of long-chain n-3 PUFA supplementation on immune markers and differences between healthy subjects and those with inflammatory conditions, because of the important implications for the transfer of information gained from studies with healthy subjects to patient populations, e.g. for establishing dose levels for specific applications. The effects of long-chain n-3 PUFA supplementation on ex vivo lymphocyte proliferation and cytokine production by lymphocytes and monocytes in healthy subjects have been studied in twenty-seven, twenty-five and forty-six treatment cohorts respectively, at intake levels ranging from 0·2 g EPA+DHA/d to 7·0 g EPA+DHA/d. Most studies, particularly those with the highest quality study design, have found no effects on these immune markers. Significant effects on lymphocyte proliferation are decreased responses in seven of eight cohorts, particularly in older subjects. The direction of the significant changes in cytokine production by lymphocytes is inconsistent and only found at supplementation levels ≥2·0 g EPA+DHA/d. Significant changes in inflammatory cytokine production by monocytes are decreases in their production in all instances. Overall, these studies fail to reveal strong dose–response effects of EPA+DHA on the outcomes measured and suggest that healthy subjects are relatively insensitive to immunomodulation with long-chain n-3 PUFA, even at intake levels that substantially raise their concentrations in phospholipids of immune cells. In patients with inflammatory conditions cytokine concentrations or production are influenced by EPA+DHA supplementation in a relatively large number of studies. Some of these studies suggest that local effects at the site of inflammation might be more pronounced than systemic effects and disease-related markers are more sensitive to the immunomodulatory effects, indicating that the presence of inflamed tissue or ‘sensitised’ immune cells in inflammatory disorders might increase sensitivity to the immunomodulatory effects of long-chain n-3 PUFA. In a substantial number of these studies clinical benefits related to the inflammatory state of the condition have been observed in the absence of significant effects on immune markers of inflammation. This finding suggests that condition-specific clinical end points might be more sensitive markers of modulation by EPA+DHA than cytokines. In general, the direction of immunomodulation in healthy subjects (if any) and in inflammatory conditions is the same, which indicates that studies in healthy subjects are a useful tool to describe the general principles of immunomodulation by n-3 PUFA. However, the extent of the effect might be very different in inflammatory conditions, indicating that studies in healthy subjects are not particularly suitable for establishing dose levels for specific applications in inflammatory conditions. The reviewed studies provide no indications that the immunomodulatory effects of long-chain n-3 PUFA impair immune function or infectious disease resistance. In contrast, in some conditions the immunomodulatory effects of EPA+DHA might improve immune function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD
Matsuyama, W., Mitsuyama, H., Watanabe, M., Oonakahara, K.-I., Higashimoto, I., Osame, M., & Arimura, K. (2005) · Chest · doi:10.1378/chest.128.6.3817 · Cited by 108 · cited 9×
“Two recent studies (Broekhuizen et al. 2005; Matsuyama et al. 2005) have investigated the effects of relatively-low supplemental intake of EPA+DHA on inflammatory markers, as well as exercise capacity, in COPD.”
BackgroundInfluentialRetractedC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525 · cited 15×
“Through the changed profiles of production of eicosanoids and other mediators, n-3 PUFA are expected to influence inflammatory processes and immune responses (Calder, 2003, 2006).”
BackgroundMethodInfluentialSelf-citationLee, T. H., Hoover, R. L., Williams, J. D., Sperling, R. I., Ravalese, J., Spur, B. W., Robinson, D. R., Corey, E. J., Lewis, R. A., & Austen, K. F. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505093121903 · Cited by 1,333
Lewis (1990) · doi:10.1056/nejm199009063231006 · Cited by 1,200
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135 · cited 2×
“2001), depression (Hibbeln, 1998, 2002) and Alzheimer’s disease (Morris et al. 2003).”
BackgroundHong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000 · cited 1×
“…mediators D-series resolvins, docosatrienes and neuroprotectins, also produced by cyclooxygenase-2 and lipoxygenase under some conditions, have been identified that also appear to be antiinflammatory and inflammation resolving (Hong et al. 2003; Marcheselli et al. 2003; Mukherjee et al. 2004).”
BackgroundConversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults
Burdge, G. C., & Calder, P. C. (2005) · Reproduction Nutrition Development · doi:10.1051/rnd:2005047 · Cited by 939 · cited 1×
“In this study linoleic and a-linolenic acids were derived from common food sources, so their effects could not be separated. a-Linolenic acid has a much larger effect than linoleic acid and increased alinolenic acid intake increases EPA levels in immune cells (Burdge & Calder, 2005).”
BackgroundSelf-citationFish consumption and the 30-year risk of fatal myocardial infarction
Daviglus, M. L., Stamler, J., Orencia, A. J., Dyer, A. R., Liu, K., Greenland, P., Walsh, M. K., Morris, D., & Shekelle, R. B. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361502 · Cited by 902
Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305841200 · Cited by 802 · cited 1×
“…mediators D-series resolvins, docosatrienes and neuroprotectins, also produced by cyclooxygenase-2 and lipoxygenase under some conditions, have been identified that also appear to be antiinflammatory and inflammation resolving (Hong et al. 2003; Marcheselli et al. 2003; Mukherjee et al. 2004).”
BackgroundCachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
Polyunsaturated fatty acids, inflammation, and immunity
Calder, P. C. (2001) · Lipids · doi:10.1007/s11745-001-0812-7 · Cited by 784
Self-citationMukherjee, P. K., Marcheselli, V. L., Serhan, C. N., & Bazan, N. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402531101 · Cited by 753 · cited 2×
“…mediators D-series resolvins, docosatrienes and neuroprotectins, also produced by cyclooxygenase-2 and lipoxygenase under some conditions, have been identified that also appear to be antiinflammatory and inflammation resolving (Hong et al. 2003; Marcheselli et al. 2003; Mukherjee et al. 2004).”
Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
Sharon, P., & Stenson, W. F. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80015-3 · Cited by 738 · cited 8×
“For example, PGE2 induces fever, pain, vasodilation and vascular permeability, while LTB4 is chemotactic for leucocytes and induces the release of reactive oxygen species by neutrophils and inflammatory cytokines (TNFa, IL-1b, IL-6) by macrophages (Lewis et al. 1990; Tilley et al. 2001).”
BackgroundInfluentialMori, T. A., Woodman, R. J., Burke, V., Puddey, I. B., Croft, K. D., & Beilin, L. J. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00407-6 · Cited by 322 · cited 6×
“Mori et al. (2003) have studied the effects of a supplemental intake of either 3.8 g purified EPA/d or 3.7 g purified DHA/d on serum IL-6 and TNFa concentrations in patients with type 2 diabetes who were hypertensive.”
BackgroundInfluentialThies, F., Miles, E. A., Nebe‐von‐Caron, G., Powell, J. R., Hurst, T. L., Newsholme, E. A., & Calder, P. C. (2001) · Lipids · doi:10.1007/s11745-001-0831-4 · Cited by 279 · cited 11×
“On the other hand, other blinded parallel studies (Thies et al. 2001a; Kew et al. 2003, 2004; Rees et al. 2006) have not found decreased IL-6 production within the EPA+DHA dose range of 1–2 g/d or at higher doses.”
BackgroundMethodResultInfluentialSelf-citationThies, F., Nebe-von-Caron, G., Powell, J. R., Yaqoob, P., Newsholme, E. A., & Calder, P. C. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.7.1918 · Cited by 232
Endres, S., Meydani, S. N., Ghorbani, R., Schindler, R., & Dinarello, C. A. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.54.6.599 · Cited by 228
Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function
Healy, D. A., Wallace, F. A., Miles, E. A., Calder, P. C., & Newsholme, P. (2000) · Lipids · doi:10.1007/s11745-000-0583-1 · Cited by 227
Self-citationTrebble, T. M., Wootton, S. A., Miles, E. A., Mullee, M., Arden, N. K., Ballinger, A. B., Stroud, M. A., Burdge, G. C., & Calder, P. C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.3.376 · Cited by 179 · cited 10×
“Trebble et al. (2003a) have reported a negative but ‘U-shaped’ dose–response relationship between long-chain n-3 PUFA intake and TNFa production, with a maximum inhibition demonstrated at a supplementary EPA+DHA intake of 1.0 g/d.”
BackgroundResultInfluentialPro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year
BLOK, W. L., DESLYPERE, J. ‐., DEMACKER, P. N. M., VAN DER VEN‐JONGEKRIJG, J., HECTORS, M. P. C., VAN DER MEER, J. W. M., & KATAN, M. B. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.2240775.x · Cited by 129
Ciubotaru, I., Lee, Y.-S., & Wander, R. C. (2003) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(03)00101-3 · Cited by 127
Effects of dietary arachidonic acid on human immune response
Kelley, D. S., Taylor, P. C., Nelson, G. J., Schmidt, P. C., Mackey, B. E., & Kyle, D. (1997) · Lipids · doi:10.1007/s11745-997-0059-3 · Cited by 89 · cited 3×
“Similarly, ARA was found to have no effect on mitogen-stimulated T-cell proliferation (Kelley et al. 1997), NK cell activity (Kelley et al.”
Background
Cited by
Wall, R., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00287.x · Cited by 1,101
Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids
Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P., & Stanton, C. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/539426 · Cited by 883
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844
Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
Adkins, Y., & Kelley, D. S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.12.004 · Cited by 557
The relationship between the fatty acid composition of immune cells and their function
Calder, P. C. (2008) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.09.016 · Cited by 499
Self-citation
Metadata
- Authors
- Sijben, J. W. C., & Calder, P. C.
- Venue
- Proceedings of the Nutrition Society
- Publisher
- Cambridge University Press (CUP)
- Published
- 2007-04-30
- Volume
- 66
- Issue
- 2
- Pages
- 237-259
- ISSN
- 0029-6651 (ISSN-L)
- 1475-2719
- OpenAlex
- W2090418019
- Cited by
- 249
- References
- 23
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.